<transcript><audio_65> И никто не может сказать, когда наступила резистентность. 5 лет – это тоже тяжелая нагрузка для пациентов, во</transcript><transcript><audio_66> Если рассматривать исследования в первой линии, когда не применялись никакие препараты гормональные, то это мутация не так частая, она всего 4%.</transcript><transcript><audio_67> предшествующей лечении использование ингибиторов ароматаза стероидных и нестероидных то до 40 процентов имеется мутации значит естественно</transcript><transcript><audio_68> пациентов с мутацией этого гена. Это очень важный ген. И важно еще и то, что существует методика определения. Есть первичная опухоль. В опухоли, допустим, уже удалена</transcript><caption><image_69>The image is a screenshot of a presentation slide from a presentation. The slide is titled "PADA-1: ESR1 is a poor prognosticator...but". The slide has a blue background with white text. On the left side of the slide, there is a line graph that shows the percentage of people who have been diagnosed with PADA 1.1. The graph is divided into two sections. 

On the right side, there are two graphs. The first graph shows that the percentage has been steadily increasing over time, while the second graph shows a decrease in the percentage.

In the center of the image, there appears to be a man in a white lab coat sitting at a desk with a microphone in front of him. He is wearing glasses and appears to have a serious expression on his face. The background is white and there are logos of White Nights and White Nights on the top left and bottom right corners.</caption><transcript><audio_70> так жидкостная биопсия берется на кровь плазма исследуется вот наличие и отсутствует эта мутация но важно еще и то что если произошел клиренс как это мы очищение</transcript><transcript><audio_71> Наоборот, у этих пациентов, как показано в правом слайде, выживаемость достоверно, беспрогрессивно выше, чем у пациентов без этой мутации.</transcript> you are somewhat targeted and no one can say when resistance has set in, for five years this is also a heavy burden for patients after the question and so on until the end, so if you are considering research on the type of first line when  they were used and what drugs are hormonal, then these mutations are not so common, over only 4 percent, but if there was previous treatment, the use of aromatase inhibitors, steroidal non-steroidal, then up to forty percent there is a mutation, which means the natural survival rate is significantly lower than the center with the mutation, this is military, this is very important, gingivitis is also important  that there is a world method for determining from a primary tumor to a tumor, let’s say it has already been removed, namely, according to analyzes, so the liquid version is taken for us, the blood is taken, the plasma is examined, the presence of this mutation is absent, but it is also important that if clearance has occurred as atoms are cleansed, then the situation changes on the contrary, on the contrary, in these  For patients, as shown in Orthodoxy, the survival rate is reliably without progressive and higher than for patients without this mutation, it is
{"source": "grass-yt-cc-by.1BgMHS5JEQA|shard_10012_18|create_multimodal_data.extract_yt_and_generate_transcripts.54|shard_10012|create_multimodal_data.generate_captions.65|shard_10012|create_multimodal_data.generate_captions.57", "params": {"id": "1BgMHS5JEQA", "channel_id": "UC5MS3dmfVp-htSABu6j4oLQ", "duration": 1709, "view_count": 971, "age_limit": 0, "like_count": 28, "channel_follower_count": 61800, "license": "Creative Commons Attribution license (reuse allowed)", "uploader_id": "@Niioncologii", "yt_tar_file": "/leonardo_work/EUHPC_E03_068/audio/fixed_download/grass-yt-cc-by//shard_10012/1BgMHS5JEQA.tar.gz"}}